Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer

Sponsor
Shengjing Hospital
Study ID
NCT05070598
Phase
PHASE2
Status
Unknown

Conditions

  • HER2-positive Gastric Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab +Pyrotinib + Nab-paclitaxel + Tegafur — DRUG
    Camrelizumab was given in the first day of each cycle,Nab-paclitaxel was given in the first day of each cycle, Pyrotinib was given everyday of each cycle, Tegafur given in the day 1-14 of each cycle

Study Details

According to the investigator's judgment, there are concomitant diseases that seriously endanger the patient's safety, or affect the patient's completion of the study (such as uncontrolled hypertension, diabetes, thyroid disease, etc.);

Key Dates

Start date
Sep 7, 2021
Status verified
Sep 2021
Primary completion
Sep 1, 2023
Completion
Mar 30, 2024

Study Design

Enrollment
35 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab +Pyrotinib + Nab-paclitaxel + Tegafur
    Camrelizumab Q3W d1 Pyrotinib d1-21 Nab-paclitaxel Q3W d1 Tegafur d1-14

Primary Outcome Measure

ORR (Objective control rate) [ Time Frame: up to 12 months ]

Central Contacts

Related Studies